Fig. 3From: Hsa-miR-181a-5p, hsa-miR-182-5p, and hsa-miR-26a-5p as potential biomarkers for BCR-ABL1 among adult chronic myeloid leukemia treated with tyrosine kinase inhibitors at the molecular responseLower expression of hsa-miR-181a-5p of 0.47 was observed in Group 1 (CML patients responsive to imatinib therapy) compared with the Control Group (blood donors) by real-time RT-qPCR (p-value < 0.05). RNU6–2 showed a similar expressionBack to article page